ES 
EN 
Breve descripción
The PODOMOUNT-pFSGS study is evaluating whether an investigational once daily oral medication called apecotrep reduces the amount of protein in the urine in adult patients with primary FSGS or genetic FSGS due to a mutation in the TRPC6 gene.
Médico del ensayo / Coordinador del estudio
Yvette Martínez
Estimated Enrollment
256
Estimated End Date
12/18/2029
Trial is for people with
Primary FSGS, as well as genetic FSGS due to TRPC6 gene mutation, diagnosed by biopsy, or genetic testing (genetic FSGS). People who ...
Study Goal
To learn more about the efficacy and safety of apecotrep and determine if it may help people with two rare kidney diseases—primary ...
What is involved for the patient?
You will receive either study drug (apecotrep) or placebo for up to 2 years. The randomization will be 1:1, meaning as many patients ...
About the drug or intervention
Apecotrep is a once daily non-immunosuppressant oral medication that is designed to protect podocytes, the cells which keep protein ...
